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Abstract
Background: While the use of probiotics to treat or prevent inflammatory bowel disease (IBD) has been proposed, to this
point the clinical benefits have been limited. In this report we analyzed the immunological activity of three strains of
Lactobacillus to predict their in vivo efficacy in protecting against experimental colitis.
Methodology/Principal Findings: We compared the immunological properties of Lactobacillus plantarum NCIMB8826, L.
rhamnosus GG (LGG), L. paracasei B21060 and pathogenic Salmonella typhimurium (SL1344). We studied the stimulatory
effects of these different strains upon dendritic cells (DCs) either directly by co-culture or indirectly via conditioning of an
epithelial intermediary. Furthermore, we characterized the effects of these strains in vivo using a Dextran sulphate sodium
(DSS) model of colitis. We found that the three strains exhibited different abilities to induce inflammatory cytokine
production by DCs with L. plantarum being the most effective followed by LGG and L. paracasei. L. paracasei minimally
induced the release of cytokines, while it also inhibited the potential of DCs to both produce inflammatory cytokines (IL-12
and TNF-a) and to drive Th1 T cells in response to Salmonella. This effect on DCs was found under both direct and indirect
stimulatory conditions – i.e. mediated by epithelial cells - and was dependent upon an as yet unidentified soluble mediator.
When tested in vivo, L. plantarum and LGG exacerbated the development of DSS-induced colitis and caused the death of
treated mice, while, conversely L. paracasei was protective.
Conclusions: We describe a new property of probiotics to either directly or indirectly inhibit DC activation by inflammatory
bacteria. Moreover, some immunostimulatory probiotics not only failed to protect against colitis, they actually amplified the
disease progression. In conclusion, caution must be exercised when choosing a probiotic strain to treat IBD.
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Introduction
The intestine is home to trillions of commensal bacteria that
participate in digestive functions while helping to protect the host
from the aggression of pathogens [1]. Commensals are not ignored
by the immune system, rather they are tolerated via a concerted
action of epithelial cells and immune cells [2–4]. The interaction
of commensals with pattern recognition receptors on the apical
surface of epithelial cells is protective against colitis [5–8], but,
commensals can also be colitogenic as several susceptible mice
when reared under germ free conditions do not develop colitis [9].
Given this dual role of bacteria – protective versus colitogenic –
the use of probiotics as therapeutic agents in IBD has been
proposed [10–12]. Probiotics can be considered as those
microorganisms that are beneficial to the host. According to an
FAO/WHO joint report ‘there is good evidence that specific
strains of probiotics are safe for human use and able to confer
some health benefits on the host, but these benefits cannot be
extrapolated to other strains without experimentation’ [13].
Indeed, given the heterogeneity of probiotics and the two-faced
character of bacteria as colitogenic or protective, it is clear that not
all microorganisms may have the same effect on the host. Instead,
it seems likely that each probiotic species, and within each species
each strain, may have distinct activities. In agreement with this,
the therapeutic effect of probiotics in patients with IBD depends
on the strain of probiotic that is used, on the stage of the disease,
and on the analyzed pathology (reviewed in [12]). Hence the
correct use of probiotics as therapeutic agents calls for a precise
knowledge of their activity.
Table 1 encapsulates the previously published studies detailing
the activity of different probiotics in protecting animals against
experimental colitis. From this it can be appreciated that the
activity of certain strains depends on the colitis model used. For
instance, in rats, Lactobacillus GG (from now on called LGG) has
been shown to have no protective effect against dinitrobenzene
sulfonic acid (DNBS)- or trinitrobenzenesulfonic acid (TNBS)-
induced colitis [14,15], a partially protective effect in the
iodoacetamide colitis model [15], and a detrimental effect in the
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DSS model [16]. It is also interesting to note that within the same
species, different strains can behave differently. For instance, in
mice, Lactobacillus plantarum DSM 15313 [17] has been shown to
partially protect against DSS colitis while the strains ACA-DC 287
[18] or Lp115 [19] have no effect in TNBS colitis.
The mechanisms of action of probiotics can be quite disparate.
They have been shown to modulate the permeability of epithelial
barriers, alter the inflammatory potential of epithelial cells,
compete with pathogens for mucosal colonization, or directly
modify the activity of immune cells (reviewed in [10,11]).
However, the principal mechanism of protection against colitis is
via a reduction in the release of pro-inflammatory cytokines, but
the pathways and cells involved in this mechanism are not yet
clear. Some probiotics like Faecalibacterium prausnitzii (whose
reduction in the normal gut microbiota has been associated with
Crohn’s disease (CD) recurrence [20]) can inhibit NF-kB
activation and IL-8 production by Caco-2 cells and reduce colonic
inflammatory cytokines in colitic mice [20]. In other cases,
probiotics like Lactobacillus casei or Lactobacillus gasseri expressing a
manganese superoxide dismutase (MnSOD) can reduce inflam-
mation via the inhibition of neutrophil recruitment [21,22].
Another mechanism of action of probiotics has been described for
a mixture of eight probiotics named VSL#3 [23] or for
Lactobacillus plantarum DSM 15313 [17], which relies upon an
attenuation of the increased epithelial barrier permeability caused
by DSS and the resulting bacterial translocation. In addition,
VSL#3 can induce the differentiation of protective T regulatory
cells [24]. This activity of probiotics may be exerted directly on
dendritic cells (DCs), which are professional antigen presenting
cells, as probiotic-loaded DCs can modulate the TNBS-induced
inflammatory reaction through the differentiation of protective T
regulatory cells [25].
DCs are pivotal in the initiation of adaptive immune responses
and can directly contact and internalize intestinal bacteria [26–
28]. Further, DCs can receive tissue conditioning by intestinal
epithelial cells that control the DC inflammatory potential [29–
31]. Hence, probiotics can interact either directly with DCs or
indirectly, via the action of epithelial cells. In this manuscript we
used a technique established in our laboratory to evaluate the
ability of three Lactobacilli strains (plantarum, LGG and paracasei
B21060) to activate DCs either directly or indirectly via the action
of epithelial cells. LGG and L. plantarum were chosen in order to
compare already published reports while L. paracasei has been
chosen for its capacity to survive the gastrointestinal tract,
temporarily associate with the intestinal wall in humans [32,33]
and inhibit T cell proliferation [34]. We found that the activity of
the three probiotics was very different. L. paracasei the more
immunomodulatory among the three strains, was able to inhibit
the inflammatory potential of pathogenic Salmonella and protect
against experimental colitis.
Results
Probiotics induce the phenotypical maturation of DCs
The first outcome of the encounter of DCs with bacteria is the
upregulation of surface activation markers. We generated DCs
from human peripheral blood monocytes (MoDCs) of 4 different
donors to assess donor-associated variability. MoDCs were
incubated for 1 h with live logarithmic-phase Lactobacilli (L.
plantarum, L. paracasei and LGG) or with Salmonella typhimurium in
medium without antibiotics at a 10:1 (bacteria:DC) ratio. Cells
were extensively washed and the medium was changed to one
containing antibiotics. Cells were tested 24 hours later for
upregulation of MHC II (HLA-DR) and costimulatory (CD80)
molecules. Consistent with a recent report on bone marrow-
derived DCs [35], the three probiotic strains induced a similar
upregulation of HLA-DR and CD80, which was however reduced
as compared to the upregulation induced by Salmonella (Fig. 1A-B,
Figure S1). Given the low multiplicity of infection and the short
exposure time, the viability of the cells (as seen by the frequency of
propidium iodide (PI) negative and annexin V negative cells), was
similar after each probiotic treatment, while Salmonella was
partially toxic (Fig. 1C).
Probiotics have a different ability to induce cytokine
production by DCs
Phenotypical activation of DCs does not necessarily correlate
with their functional activation [36] and the type of cytokines
released can have an impact on T cell polarization. Therefore, we
analyzed the production of IL-12p70, IL-10, TNF-a and IL-12p40
by MoDCs after 24 h treatment with bacteria, as above. Salmonella
was a strong inducer of all of the tested cytokines, while the three
Lactobacilli elicited differential cytokine release (Fig. 2A). L.
plantarum and LGG induced a cytokine response that was very
similar to that of Salmonella, while L. paracasei induced lower levels
of IL-12p70, TNF- a and IL-10 when compared to Salmonella.
Thus, the only strain displaying a reduced inflammatory potential
was L. paracasei.
It has been shown that IL-10 can negatively regulate the
expression of IL-12p70 [37]. To test whether an early increase in
IL-10 release could impact on IL-12 production, we analyzed IL-
10 release during the initial phases of DC activation (4–6 hours).
The levels of IL-10 were not higher in any of the cultures of DCs
with Lactobacilli during the times at which IL-12p70 was low,
thereby suggesting IL-12p70 induction is delayed in comparison to
Salmonella and is not controlled by IL-10 (Fig. 2B).
The difference in cytokine production reflects different T
cell polarizing ability
Cytokine release by DCs is important to drive the polarization
of T cells towards Th1, Th2, Th17 or T regulatory cells. Given the
differences observed in cytokine production we analyzed the
capacity of bacteria-treated DCs to activate and polarize T cells.
DCs were incubated with live bacteria and then cultured with
highly purified allogeneic naı¨ve CD4+CD45RA+ T cells. As shown
in Figure 3A, all three Lactobacilli were less potent in inducing T
cell proliferation when compared to Salmonella, probably reflecting
their reduced ability to upregulate surface activation markers
(Fig. 1A–B). When we analyzed the cytokines produced by T cells
we found that T cells activated with paracasei-treated DCs were
affected in their ability to release IFN-c, IL-2, IL-10 and IL-6
(Fig. 3B). In contrast, L. plantarum-treated DCs activated T cells
similarly to S. typhimurium-treated cells in terms of IFN-c release
but induced less IL-10, while LGG-treated DCs induced the
opposite, more IL-10 and less IFN- c (Fig. 3B). There was no
difference in IL-17 production (p.0.05). Some probiotics (i.e. L.
casei and reuteri) can induce the development of T regulatory cells
[24,25,38]. However, the different Lactobacilli and Salmonella
displayed a similar ability to drive CD25+Foxp3+ T regulatory
cells (Figure S2).
L. paracasei is less inflammatory on epithelial cells
It is likely that the first cells interacting with the intestinal flora
are the epithelial cells (ECs) that line the intestinal wall, especially
in IBD patients which display a reduced mucous layer [39]. For
this reason, we studied the response of monolayers of ECs to
probiotics (56107 CFU/TW) incubated from the apical (luminal)
Immunomodulatory Probiotics
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Figure 1. DCs are phenotypically similarly activated by Lactobacilli. DCs were incubated or not with the reported live bacterial strains for 1 h
in medium without antibiotics, washed and incubated for 23 h in medium with antibiotics. Cells were stained for HLA-DR and CD80 expression and
analyzed by FACS. A. % of cells highly positive for the marker is reported. B. Mean fluorescence intensity (MFI) expression of markers is reported. C.
Viability of the cells after 24 h incubation with bacteria. Cells were stained with propidium iodide (PI) and annexin V and analyzed by FACS. Cells
double negative for both markers are considered viable cells. Error bars: standard deviations on values obtained on 4 different donors.
doi:10.1371/journal.pone.0007056.g001
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side. One hour after incubation, bacteria were washed out and
medium was changed with one containing antibiotics (gentamycin
100 mg/mL). The different bacteria had no effect on the viability
of the cells (not shown). We analyzed the release of IL-8, a
chemokine involved in the recruitment of neutrophils, and of
thymic stromal lymphopoietin (TSLP) and TGF-b, cytokines
shown to inhibit the inflammatory potential of DCs [30,31]. We
found that while Salmonella induced the release of IL-8 as early as
4 hours after bacterial treatment, all tested Lactobacilli induced
negligible IL-8 release (Fig. 4). This probably reflects their inability
to invade epithelial cells. L. paracasei displayed a greater ability to
induce the release TGF-b whose levels were statistically higher
than basal levels only at 4 and 6 h post incubation (Fig. 4;
p,0.05).
In addition, L. paracasei induced TSLP expression that peaked at
48 h from infection, while both L. plantarum and LGG induced a
very transient production of TSLP. Salmonella induced sustained
TSLP release that did not reach the level of L. paracasei (Fig. 4).
Interestingly, TSLP mRNA levels were sustained in ECs treated
with all bacteria (Figure S3), but the meaning of this observation
remains to be understood. One could speculate that TSLP protein
is either not released at later time points, or is easily degraded in
response to LGG and L. plantarum. By contrast, L. paracasei and
Salmonella incubation may lead to increased release and/or
stabilization of the protein.
L. paracasei inhibits the inflammatory potential of DCs
Having shown that L. paracasei was the least inflammatory
among the three Lactobacilli strains, we focused on this strain for
further experiments. We utilized three different conditions
involving the interaction between bacteria, epithelial cells and
DCs. DCs were either incubated with: a. L. paracasei (LP) and
Salmonella (SL) individually or together; b. EC supernatant for 24 h
and then subsequently with each bacteria; c. supernatants of ECs
pre-incubated for 24 h with L. paracasei (Sn caco LP) on the apical
side and then (24 h later) with each bacterial strain. As shown in
Fig. 5, L. paracasei had a strong anti-inflammatory effect on DCs
both when directly co-incubated with Salmonella and indirectly
when supernatants of LP-treated ECs were incubated with DCs
before exposure to Salmonella. The co-incubation of DCs with LP
and Salmonella significantly reduced the ability of Salmonella to
induce IL-12p70 and TNF-a, while not altering its ability to
Figure 2. DCs incubated with different bacterial strains produce a distinct cytokine profile. A. DCs were incubated or not with the
reported live bacterial strains for 1 h in medium without antibiotics, washed and incubated for 23 h in medium with antibiotics. Culture supernatants
were collected and tested for cytokine contents by ELISA. Each symbol represents a different DC donor. Red lines represent mean values. *, p,0.05;
**, p,0.01. S. typhim.: S. typhimurium; L. plant.: L. plantarum; L. parac.: L. paracasei. B. To analyze the kinetic of cytokine production, DCs were
incubated or not with the reported live bacterial strains for 1 h in medium without antibiotics, washed and incubated for 3–5 h in medium with
antibiotics. Culture supernatants were collected and tested for cytokine release by ELISA. Error bars: standard deviations on values obtained on 4
different donors.
doi:10.1371/journal.pone.0007056.g002
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Figure 3. Lactobacilli-treated DCs have different ability to induce T cell proliferation and cytokine production. A. T cell proliferation:
DCs were incubated or not with the reported live bacterial strains for 1 h in medium without antibiotics, washed and incubated for 23 h in medium
with antibiotics. Bacteria-treated DCs were washed and incubated with naı¨ve CD4+CD45RA+ cells for 3 days, followed by a 16-hours pulse with 1 mCi
[3H] thymidine (Amersham, Milan). 3H-thymidine incorporation is shown. Each symbol represents a different DC donor. Red lines represent mean
values. *, p,0.05. S. typh: S. typhimurium; L. plan: L. plantarum; L. par: L. paracasei. B. Cytokine release: Bacteria-treated DCs were incubated with naı¨ve
CD4+CD45RA+ cells for 5 days (Ratio 1:10 DC:T cells). Cell culture supernatants were collected and cytokines measured by ELISA or CBA Flex set. Error
bars: standard deviation on values obtained on 3 different donors. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0007056.g003
Immunomodulatory Probiotics
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Figure 4. L. paracasei induces increased levels of TGF-b and TSLP. Caco-2 cells were grown as monolayers in the upper chamber of a transwell
filter and incubated with live bacteria (56107 CFU/TW) upon the apical surface (top chamber). One hour after incubation, bacteria were washed out
and medium was changed with one containing antibiotics. Culture supernatants were collected 3, 5, 23 and 47 hours later from the bottom chamber
and tested for cytokine release. Error bars: standard deviations on values obtained in 2 different experiments. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0007056.g004
Immunomodulatory Probiotics
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Figure 5. L. paracasei inhibits the release of inflammatory cytokines both directly and indirectly on DCs. Each treatment is schematically
reported below the graphs. Three situations were analyzed (a, b, c). a. DCs were incubated or not with the reported live bacterial strains either
separately (SL, Salmonella; LP, L. paracasei) or together (LP+SL) for 1 h in medium without antibiotics, washed and incubated for 23 h in medium with
antibiotics. b. Caco-2 cells were grown as monolayers in the upper chamber of a transwell filter. 24 h from achievement of a TER of 300 OhmNcm2
supernatants (sn Caco) were collected from the bottom chamber and used to pre-treat DCs for 24 h before bacterial incubation as in a. c. Caco-2 cells
were grown as monolayers in the upper chamber of a transwell filter and incubated with L. paracasei (56107 CFU/TW) upon the apical surface (top
chamber). One hour after incubation, bacteria were washed out and medium was changed with one containing antibiotics. Culture supernatants (sn
caco LP) were collected 24 hours later from the bottom chamber, filtered and used to pre-treat DCs for 24 h before bacterial incubation as in a. 24 h
after bacterial treatment of DCs cell culture supernatants were collected and cytokines analyzed by ELISA. Error bars: standard deviations on values
obtained on 3 different donors. *, p,0.05; **, p,0.01
doi:10.1371/journal.pone.0007056.g005
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promote IL-10 and IL-6 production (Fig. 5). A similar scenario was
observed when DCs were first incubated with supernatants of LP-
treated ECs and then infected with Salmonella. However, as we
have already described [29], the incubation of DCs with
unconditioned EC supernatant also reduced the ability of DCs
to release IL-12p70 but not TNF in response to Salmonella.
Therefore, the exposure of ECs to LP strongly inhibited the
inflammatory response of Salmonella on DCs by inhibiting both IL-
12p70 and TNF-a release (Fig. 5). This effect may be mediated
either by LP-induced release of anti-inflammatory mediator/s by
ECs, or by some component of L. paracasei that is translocated
across the monolayer. The involvement of whole LP translocated
across the monolayer is unlikely, as we could not detect intact
bacteria from the basolateral side (not shown) and supernatants
were filtered before incubation with the DCs. We could not detect
any effect of LP on IL-6 or IL-10 (Fig. 5).
We then analyzed whether the factor(s) involved in the anti-
inflammatory effect was a soluble mediator and could be found in
the culture supernatant of L. paracasei. DCs were coincubated with
Salmonella and either L. paracasei or its culture supernatant (sn LP:
derived from the same amount of CFUs used for DC incubation).
Interestingly, the LP supernatant alone (7% volume/volume of
tissue culture medium) was extremely efficient in inhibiting the DC
release of inflammatory cytokines while it was unable to alter the
ability of DCs to release IL-10 or IL-12p40 (Fig. 6). When LP was
extensively washed before incubation with DCs it lost the ability to
inhibit the DC release of inflammatory cytokines in response to
Salmonella (Fig. 6), suggesting that the anti-inflammatory effect of L.
paracasei is dependent on a soluble metabolite or mediator. It is
likely that this mediator(s) is not released during the limited time of
LP in culture with the DCs as we could not detect LP growth
during the 1 h incubation time with DCs (most likely due to the
aerobic culture conditions, not shown). Further diluting the LP
culture supernatant 1 to 5 (1.4% volume/volume) but also 1 to 10
(0.7% volume/volume) was still able to inhibit the release of IL-
12p70 and TNF-a, indicating the high efficacy of the soluble
mediator(s) (Fig. 6).
Coincubation of Salmonella and L. paracasei affects the
ability of DCs to activate Th1 T cells
Having shown that the coincubation of DCs with LP and
Salmonella (SL) drastically reduced the ability of DCs to release IL-
12p70 while preserving IL-10 production we analyzed the ability of
these DCs to polarize inflammatory T cells. We treated DCs with
either LP, or SL or the two together. Cells were then incubated with
highly purified naı¨ve T cells and cytokine release in culture
supernatants was tested. As shown in Figure 7 (see the situation a), T
cells activated with DCs that were incubated with both Salmonella
and L. paracasei were highly impaired in their ability to release IL-2,
IL-10, IL-6 and IFN-c. We could not observe any difference in IL-
17, IL-13 or IL-5 suggesting that LP+SL treated DCs were still
capable of inducing Th17 or Th2 polarization (Fig. 7).
DCs incubated with supernatants of L. paracasei treated
ECs are affected in their ability to drive Th1 T cells
DCs incubated with supernatants of LP-treated ECs are affected
in their ability to release IL12-p70 and TNF-a in response to
Salmonella. Consequently, we evaluated whether this had an impact
Figure 6. L. paracasei culture supernatant is responsible for the anti-inflamamtory activity of the bacterium. DCs were incubated or not
with the reported live bacterial strains either separately (SL, Salmonella; LP, L. paracasei) or together (LP+SL) or in the presence of culture supernatants of
L. paracasei corresponding to the exponential growth of the same amount of CFU of bacteria used to treat the DCs. The culture supernatant (sn LP) was
used either undiluted or diluted 1/5, 1/10, 1/100 that correspond to nearly 7%, 1,4%, 0,7%, and 0,07% volume/volume of tissue culture medium,
respectively. Cells were incubated with the different treatments for 1 h in medium without antibiotics, washed and incubated for 23 h in medium with
antibiotics. Cytokine release was analyzed by ELISA. Error bars: standard deviations on values obtained on 3 different donors. *, p,0.05; **, p,0.01
doi:10.1371/journal.pone.0007056.g006
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Figure 7. L. paracasei inhibits the ability of DCs to activate T cells. Three situations were analyzed (a, b, c) as in fig. 6 DCs were incubated or
not with the reported live bacterial strains either separately (SL, Salmonella; LP, L. paracasei) or together (LP+SL) for 1 h in medium without
antibiotics, washed and incubated for 23 h in medium with antibiotics. a. Caco-2 cells were grown as monolayers in the upper chamber of a transwell
filter. 24 h from achievement of a TER of 300 OhmNcm2 supernatants (sn Caco) were collected from the bottom chamber and used to pre-treat DCs
for 24 h before bacterial incubation as in a. b. Caco-2 cells were grown as monolayers in the upper chamber of a transwell filter and incubated with L.
paracasei (56107 CFU/TW) upon the apical surface (top chamber). One hour after incubation, bacteria were washed out and medium was changed
with one containing antibiotics. Culture supernatants (sn caco LP) were collected 24 hours later from the bottom chamber, filtered and used to pre-
treat DCs for 24 h before bacterial incubation as in a. Cells were then washed and incubated with naı¨ve CD4+CD45RA+ cells for 5 days (Ratio 1:10
DC:T cells). Cell culture supernatants were collected and cytokines measured by ELISA or CBA Flex set. Error bars: standard deviations on values
obtained on 3 different donors. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0007056.g007
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on Th1 T cell polarization. To accomplish this, DCs were pre-
incubated with supernatants from either untreated (sn caco:
situation b) or paracasei-treated ECs (sn caco LP: situation c) for
24 h, and then with either LP or Salmonella for an additional 24 h
before incubation with naı¨ve T cells for 5 days. As shown in Fig. 7,
the preincubation of DCs with LP-treated-EC supernatants prior
to Salmonella infection, drastically reduced the DC’s ability to
activate T cells and drive their polarization to Th1 T cells as
evidenced by a decrease in IFN-c, IL-2 and IL-6 production.
There was no difference in IL-17 and IL-13 production (p.0.05)
while IL-10 and IL-5 levels were also reduced in culture
supernatants (Fig. 7). This indicates that the incubation of ECs
with L. paracasei has a strong effect on the ability of DCs to activate
T cells in response to Salmonella.
The in vitro activity of probiotics predicts their efficacy in
vivo
We next compared the activity of the three Lactobacilli in
protecting mice against an acute model of colitis. We chose the
DSS colitis model as it provokes a strong inflammatory response
that is primarily mediated by DCs [40]. Mice were pretreated i.g.
for 7 days with 1010 CFUs of either L. plantarum, LGG or L.
paracasei, or with PBS as a control. Then mice received for 5 days
2% DSS in the drinking water and the development of colitis was
followed over time by measurement of body weight, stool
consistency and presence of blood in the feces. We found that L.
plantarum and LGG, consistent with their ability to strongly activate
DCs, were not only ineffective in protecting against colitis, but
were in fact detrimental. Indeed, LGG- and L. plantarum-treated
mice displayed an increased disease activity index (DAI) and all
died between 10 and 12 days from DSS administration (Fig. 8). In
contrast, mice receiving L. paracasei although displaying a similar
weight loss as PBS-DSS treated controls, showed a delay in colitis
development and a reduced severity of disease (as shown by
reduced DAI in Fig. 8B).
Discussion
IBD is a multifactorial disorder caused by both genetic and
environmental factors. The host microflora contributes to disease
development and perpetuation as colitis-susceptible mice reared
under germ free conditions do not develop the disease and IBD
patients treated with antibiotics experience amelioration of
symptoms. Further, a colitogenic flora able to disseminate the
inflammatory condition has been identified in mice [41]. Finally, it
has been shown that a reduced proportion of mucosal associated
Faecalibacterium prausnitzii is associated with a higher risk of
postoperative recurrence of ileal CD [20]. Hence, a lot of effort
has been undertaken to find ways to reestablish a protective
intestinal flora. In this context, the use of probiotics as therapeutic
or preventive agents in IBD has long been proposed, with however
Figure 8. L. paracasei protects against DSS colitis. Mice (n = 6) were administered intra gastrically (i.g.) once a day for 7 days with 200 ml PBS
containing 1010 CFUs of bacteria or plain PBS as a control. Mice were then fed with 2% DSS dissolved in the drinking water for 5 days without
bacteria, followed by 7 days of plain water and assessed over time for colitis development. A. Body weight was measured at baseline and every day
for the duration of the experiment. Weight change was calculated as percentage change in weight compared with baseline. L. plant.: L. plantarum; L.
parac.: L. paracasei. Asterisks refer to statistical analysis of the groups LGG or L. plantarum versus DSS PBS positive control group. *, p,0.05; **,
p,0.01; = , dead animals. B. Disease activity index (DAI) was measured as reported in Materials and Methods. DAI at 4, 5, 7 days is shown per each
group. The scatterplot shows a line at the mean of each group with error bars. Dashed lines identify one standard deviation above and below the
group means. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0007056.g008
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limited clinical efficacy [12]. Here we employed both complex in
vitro culture systems and an in vivo mouse model to study the
immunological effect and anti-inflammatory properties of three
different probiotic strains: L. plantarum, LGG and L. paracasei. We
show that Lactobacillus strains dramatically differed in their ability
to activate DCs and to drive the polarization of T cells. In
particular, we found that L. plantarum and LGG were more similar
to Salmonella in terms of DC activation and T cell polarization than
L. paracasei. The latter proved very poor in activating DCs and in
inducing cytokine production (both inflammatory and non-
inflammatory). Furthermore, all Lactobacilli induced the develop-
ment of CD25+Foxp3+ T regulatory cells similarly to Salmonella.
When we tested the capacity of the different Lactobacilli to
activate epithelial cells we found that L. paracasei induced an
increased release of TGF-b and TSLP. Both factors play an
important role in driving the differentiation of non-inflammatory
human DCs [30,31]. Moreover, L. paracasei affected the ability of
DCs to respond to Salmonella typhimurium both directly (when co-
incubated with Salmonella) and indirectly (after treatment of DCs
with supernatants from ECs which had been treated with L.
paracasei upon their luminal side). Co-incubation of DCs with
Salmonella and L. paracasei together strongly inhibited the release of
IL-12p70 while leaving the release of IL-10 untouched. This
resulted in reduced differentiation of Th1 T cells. Similarly, the
incubation of DCs with supernatants of ECs treated with L.
paracasei affected the release of IL-12p70 and TNF-a and the
development of Th1 T cells. This suggests that once in the
intestine, L. paracasei may act directly on intraepithelial DCs
limiting their ability to induce inflammation even to potent
inflammatory bacteria, but they may also indirectly inhibit the
activity of DCs that do not enter directly in contact with paracasei,
via conditioning of ECs. We do not yet know whether this effect is
mediated by a soluble factor released by epithelial cells or by a
bacterial-derived mediator transcytosed across the epithelial cells.
Both possibilities are likely as we found that the direct effect of L.
paracasei on DCs is indeed dependent on an LP released soluble
mediator. The culture supernatant of L. paracasei was, by itself,
sufficient to inhibit the release of IL-12p70 and TNF-a, but not IL-
10, by DCs in response to Salmonella. This effect was very strong as
it occurred even at very low concentrations of bacterial
supernatant (0.7% of the tissue culture volume). Other examples
of soluble mediators that are responsible for the anti-inflammatory
activity of bacteria have been reported. For instance, Faecalibacter-
ium prausnitzii also inhibits IL-8 production induced by IL-1b in
Caco-2 cells via an unknown soluble mediator [20]. Similarly,
Lactobacillus acidophilus exerts its activity via the interaction of the
surface (S) layer A protein (SlpA) with the C-type lectin DC-SIGN
on dendritic cells [42]. However, it is unlikely that an S layer
protein is the mediator of the anti-inflamamtory activity of L.
paracasei for two reasons. First, L. paracasei’s activity is exclusively
dependent on a soluble mediator while S layer proteins are also
present on the surface of the bacterium. Second, while SlpA alone
induces the release of IL-10, as expected through its activation of
DC-SIGN, L. paracasei supernatant is unable to induce IL-10
production by DCs. Hence, it remains to be analyzed what is the
nature of the soluble mediator released by L. paracasei and what is
the mechanism of inhibition of IL-12p70 and TNF-a release while
sparing IL-10 release by DCs.
Therefore, we have described a new property of probiotics,
which is to inhibit cytokine release and T cell activation by DCs in
response to strong immunogens like Salmonella. The effect of L.
paracasei on DC activation was not limited to Salmonella but was also
active against immunogenic Lactobacilli (not shown), suggesting that
L. paracasei may also inhibit the activation of the immune system in
response to immunogenic commensal bacteria. This is likely the
case as when we pretreated mice for 7 days with the three different
Lactobacilli before exposure to DSS, only L. paracasei was protective.
As DCs have been shown to regulate the outcome of DSS colitis
[40] it is likely that the probiotic effect observed in vivo is
dependent on the capacity of L. paracasei to inhibit the
inflammatory potential of DCs.
Recently, it has been shown that the logarithmic growth phase
of Lactobacilli is associated with the induction of anti-inflammatory
genes [43]. While all of the bacterial preparations used in the
current study were logarithmic, still we observed that LGG and L.
plantarum NCIMB8826 were detrimental as they induced the death
of DSS-treated mice, suggesting that these strains are inflamma-
tory independently of their growth phase. A recent report has
shown that the ratio between IL-10 and IL-12 production after
treatment of human peripheral blood mononuclear cells with
probiotics, was predictive of in vivo probiotic activity in the TNBS
colitis mouse model [44]. The authors showed that a higher IL-
10/IL-12 ratio correlated with better in vivo efficacy. Accordingly,
in our study, based on MoDCs, we show a worse DAI in mice
pretreated with plantarum that had a lower IL-10/IL-12 ratio than
the other two strains (plantarum: 0,877; LGG: 1,222; paracasei:
1,176). However, the IL-10/IL-12 ratio would not explain the
better outcome of L. paracasei versus LGG that displayed a similar
cytokine ratio. It is important to note that L. paracasei was a poor
inducer of cytokines (both inflammatory and non-inflammatory)
and impacted on the ability of DCs to produce inflammatory
cytokines in response to pathogens, suggesting that this could
represent a new class of immunomodulatory probiotics that do not
act via the induction of tolerogenic responses.
In conclusion, we show that probiotics should be divided into
immunostimulatory and immunomodulatory according to their
ability to interact with immune and non-immune cells, and their
clinical use should be tailored accordingly. For instance, LGG,
which is immunostimulatory has been shown to be more
appropriate in the prevention of nosocomial rotavirus-dependent
diarrhea in infants [45] or in decreasing the incidence of atopic
dermatitis [46], than as an additive therapy in children with CD
[47] or in CD patients after surgery [48]. In contrast L. paracasei,
which is immunomodulatory, may be used to dampen inflamma-
tory responses and may be recommended to maintain the
remission phase in IBD. Hence, each probiotic strain should be
characterized for their immune activity before being proposed for
clinical applications.
Materials and Methods
Mice and Bacterial strains
C57/BL6 mice were purchased from Charles River laborato-
ries. All mice were maintained in microisolator cages in a specific
pathogen-free animal facility. All experiments were performed in
accordance with the guidelines established in the Principles of
Laboratory Animal Care (directive 86/609/EEC) and approved
by the Italian Ministry of Health.
S. typhimurium strain SL1344 was provided by G. Dougan
(The Wellcome Trust Sanger Institute, UK) and grown in LB
medium. Lactobacilli strains were: L. plantarum, NCIMB8826 WT;
L. paracasei B21060 (Flortec, Bracco); L. rhamnosus GG (Dicoflor 30,
Dicofarm). All Lactobacilli were grown overnight anaerobically at
37uC in MRS broth (Biokar Diagnostic) without shaking. Bacteria
were restarted at a 1:50 dilution and grown to an OD600 = 0.6
when the growth is exponential. Bacterial cultures were plated to
count effective CFUs. L. paracasei supernatant was obtained after
centrifugation of the equivalent amount of CFUs of exponential
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phase bacteria used for DC treatment. L. paracasei supernatant was
used either undiluted, or diluted 1:5, 1:10 or 1:100 corresponding
to nearly 7%, 1,4%, 0,7%, and 0,07% volume/volume of tissue
culture medium, respectively.
Cells and reagents
DCs were derived from human peripheral blood monocytes
selected with anti-CD14 antibodies coupled to magnetic beads
(Miltenyi, Bologna, Italy) [49]. CD14+ cells were incubated for 6
days in complete medium containing granulocyte-macrophage
colony-stimulating factor (GM-CSF, 50 ng/mL; Peprotech) and
interleukin-4 (20 ng/mL; Peprotech, Milan, Italy) in order to
obtain immature MoDCs.
Bacterial treatments and assessment of MoDC viability
MoDCs were incubated for 1 h with live logarithmic-phase
Lactobacilli (L. plantarum, L. paracasei and LGG) or with Salmonella
typhimurium in medium without antibiotics at a 10:1 (bacteria:DC)
ratio. Cells were extensively washed and the medium was changed
to one containing gentamycin (100 mg/ml). Cells were tested
24 hours later for viability after double staining with FITC-
conjugated Annexin V (BD PharMingen, San Diego, CA) and
1.25 mg/ml propidium iodide (Sigma Chemical Co.), and
analyzed by flow cytometry. Annexin V/propidium iodide double
negative cells are indicative of viable cells.
Epithelial cell monolayers
Caco-2 cells were seeded in the upper chamber of a transwell
filter (Costar 3 mm diameter of pores) for 7–10 days until a trans-
epithelial resistance (TER) of 300 OhmNcm2 was achieved.
Epithelial cell monolayers were incubated with bacteria
(56107 CFU/TW) upon the apical surface (top chamber). One
hour after incubation, bacteria were washed out and medium was
changed with one containing antibiotics (gentamycin 100 mg/mL).
Culture supernatants were collected 24 hours later from the
bottom chamber (facing the basolateral membrane), filtered
through a 0.2 mm filter (Nalgene) and used to activate MoDCs.
MoDCs were incubated for 24 hours in culture supernatant
(1:2) and then treated or not with bacteria (10:1 bacteria to DC)
for 1 h in medium without antibiotics. Subsequently bacteria were
washed out and cells were left in culture for an additional 23 h in
medium containing gentamycin 100 mg/mL. Analysis of cytokines
released by epithelial cells or DCs was carried out by testing
culture supernatants.
MoDC T-cell co-cultures
MoDCs were collected after 24 hours of incubation with the
different stimuli and then incubated with purified allogeneic
CD4+CD45RA+ T cells (Miltenyi) in 48-well plates (at a ratio of 10
T cells to 1 DC). To measure T cell proliferation: MoDC-T cell
were co-cultured for 72 hours, followed by a 16-hour pulse with
1 mCi [3H] thymidine (Amersham, Milan). Cell-associated radio-
activity was detected after Cell harvesting (TomTec) on filtermats
using a Betaplate Counter (MicroBeta TriLux, PerkinElmer).
To measure cytokine release: After 5 days of MoDC-T cell co-
culture, supernatants were collected and directly analyzed for
cytokine measurements.
DSS colitis
6 mice per group were administered intra gastrically (i.g.) once a
day for 7 days with 200 ml PBS containing 1010 CFUs of bacteria
grown as above. Control mice were administered with plain PBS.
Mice were then fed with 2% DSS dissolved in the drinking water
for 5 days without probiotics, followed by 7 days of plain water
and analyzed over time for colitis development. Mice were
weighed every day and feces were collected to measure consistency
and the presence of blood by HEMOCCULT (BeckmanCoulter,
Inc). At day 13 after DSS treatment mice were sacrificed.
Assessment of disease activity
Body weight was assessed at baseline and every day for the
duration of the experiment. Weight change was calculated as
percentage change in weight compared with baseline. Animals
were monitored clinically for rectal bleeding, diarrhea and general
signs of morbidity, including hunched posture and failure to
groom. Disease activity index (DAI) is the combined score of
weight loss, stool consistency, and bleeding. Scores were defined as
follows: body weight loss, 0, no loss; 1, 5%–10%; 2, 10%–15%; 3,
15%–20%; 4, 20%; stool consistency, 0, normal; 2, loose stool; 4,
diarrhea; bleeding, 0, no blood; 2, presence of bleeding; and 4,
gross bleeding [50]
Cytokine measurements
IL-6, IL-2, IL-12p40, IL-17, IL-12p70, IL-10, IFN-c, TNF-a and
TGF-b concentrations were determined by commercially available
ELISA (R&D systems) or Cytokine bead array (Becton Dickinson).
Optical densities were measured on a Bio-Rad Dynatech
Laboratories ELISA reader at a wavelength of 450 nm (Hercules,
CA, USA). CBA-associated Cytofluorimetry was measured by
FACS array (Becton Dickinson). Limit of detection of cytokines by
CBA,10 pg/ml (for all of them) and by R&D systems
TSLP,5 pg/ml, TGF-b,30 pg/ml, IL-8,30 pg/ml.
Statistical analysis
Student’s paired t test was used to determine the statistical
significance of the data. Significance was defined as *, p,0.05; **,
p,0.01 (two-tailed test and two-sample equal variance parame-
ters). Statistic calculations were performed by JMP 7 software (SAS
Cary).
Supporting Information
Figure S1 Probiotics induce a similar activation of surface
markers on DCs. DCs were incubated or not with the reported live
bacterial strains for 1 h in medium without antibiotics, washed
and incubated for 23 h in medium with antibiotics. Cells were
stained for HLA-DR and CD80 expression and analyzed by
FACS. Histograms show surface expression of CD80 (left) or
HLA-DR (right) in response to the different bacteria (black
histograms). Blue histograms show marker expression in unstimu-
lated cells.
Found at: doi:10.1371/journal.pone.0007056.s001 (0.24 MB PPT)
Figure S2 Lactobacilli do not differ in their ability to drive
CD4+CD25+Foxp3+ T regulatory cells. DCs were incubated or
not with the reported live bacterial strains for 1 h in medium
without antibiotics, washed and incubated for 23 h in medium
with antibiotics. Cells were washed and incubated with naı¨ve
CD4+CD45RA+ cells for 5 days (Ratio 1:10 DC:T cells). Cells
were collected and analyzed by cytofluorimetry for the expression
of CD4, CD25 and intracellular Foxp3. S. typhim., Salmonella
typhimurium; L. plant., L. plantarum; L. parac., L. paracasei
B21060; LGG, L. rhamnosus GG. One representative of three
independent experiments is shown.
Found at: doi:10.1371/journal.pone.0007056.s002 (0.09 MB PPT)
Figure S3 L. paracasei induces increased levels of TSLP Caco-2
cells were grown as monolayers in the upper chamber of a
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transwell filter and incubated with bacteria (56107 CFU/TW)
from the apical surface (top chamber). One hour after incubation,
bacteria were washed out and medium was changed with one
containing antibiotics (gentamycin 100 mg/mL). Cells were
collected 3, 5, 23 and 48 hours later from the bottom chamber.
mRNA was isolated and retrotranscribed. Quantitative RT-PCR
showing TSLP mRNA expression levels normalized to TBP gene
are shown. The bars represent normalized TSLP expression values
(TSLP/TBP ratios). One of two independent experiments is
shown.
Found at: doi:10.1371/journal.pone.0007056.s003 (0.14 MB PPT)
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